Abstract 4328
Background
The treatment of cancer has improved and many of the patients’ will return to work. Cancer treatments can have significant impact on work- and functional abilities creating challenges for return to work. Occupational health care services have an important role in supporting patients’ Return-to-Work-process. The purpose of the study was to a) explore cancer patients experiences on support received from occupational health services and b) explore how the services need to be developed.
Methods
Qualitative approach with thematic interview as data collection method was used to explore breast cancer patientś experiences (N = 8). The data was analysed by using thematic content analysis. Five of the cancer patients interviewed had already returned to work after cancer treatments and three were returning work in short period of time.
Results
The main challenges cancer patients confronted formed four categories; factors related to work, workplace, cancer and treatment types and to individual factors. The experienced support by occupational health services varied. The requirement to assess ability to work in the time of 90 sickness days was filled and planning the return-to-work in collaboration between occupational health care, cancer patient and employer occurred in most cases. However, otherwise, the role was passive and patients wished to have more contact with professionals working in the occupational health services.
Conclusions
Previous research highlights the need of collaboration between cancer patients and occupational health care services. Based on the study results, this collaboration needs to be enhanced. Occupational health care providers need to co-ordinate more actively the return-to-work -processes even the special health care is responsible for cancer treatments. From individual perspective, information, psychosocial support and regular evaluation of ability to work are forms of services cancer patient need from the occupational services for successful Return-to-Work. Results of this study can be used to developing occupational health services in national and international context.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Turku University of Applied Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract